GEN Exclusives

More »

GEN News Highlights

More »
Dec 11, 2006

Protherics to Take Over MacroMed

  • Protherics has acquired MacroMed in a $25-million all-stock acquisition. Protherics thus gains the company’s lead product, OncoGel, a sustained-release formulation of paclitaxel being developed for local administration in the treatment of esophageal and brain cancer. OncoGel is currently in Phase II trials.

    "The merger is very significant for MacroMed because it helps ensure that OncoGel progresses toward commercialization," says MacroMed CEO, Thomas Bergmann.

    Protherics plans to continue MacroMed operations at the current West Valley City, Ut facility. The acquisition is expected to complete in early 2007.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?